Our emerging business and technology (EB&T) lawyers provide growth businesses with personalized and effective long-term representation, from initial start-up to maturity, utilizing lawyers in offices in major technology centers throughout the United States, Europe, the Middle East, and Asia. We offer clients a pragmatic, business-oriented approach to solving a range of complex legal problems, cost-efficient legal services, and value-added access to sources of capital and other business resources.
Our lawyers provide legal services well suited to rapidly growing technology and life sciences companies, including guidance on corporate finance, mergers and acquisitions (M&A), initial public offerings (IPOs), intellectual property (IP) protection, employment, international expansion, regulatory, cybersecurity, and tax issues. We leverage the experience and domain knowledge developed through our representation of many of the leading technology, pharmaceutical, biotechnology, medical device, financial services, and energy companies. We look to establish life-long lead counsel relationships, from early-stage development through global expansion and initial funding to an IPO or other liquidity event.
Our reputation and relationships help entrepreneurs and investors make profitable decisions and valuable connections. We keep clients close to the financing resources that fund today’s growing companies through our established relationships with the venture capital and investment banking communities in the Boston, New York, Mid-Atlantic, Silicon Valley, Southern California, and international markets.
Morgan Lewis serves clients in the healthcare and life sciences fields, including pharmaceutical, biotech, medical device, and ag tech businesses; information technology, including digital media, social media, software, and cloud-based entities; ecommerce companies; and fintech, renewable energy, telecommunications, and wireless entities. In particular, our leading energy, FDA and healthcare, financial institution, and telecommunications regulatory practices provide a hard-to-match depth of industry knowledge.
Our life sciences industry clients range from start-ups to emerging biotechs to established global pharmaceutical companies, as well as the venture capital, private equity, and investment banking firms focused on the life sciences industry. Our lawyers represent life sciences industry clients in mission-critical transactions, such as collaborations, corporate partnering, financing, and M&A.
Our team helps life sciences clients build, negotiate, and implement essential strategic alliances with other pharmaceutical, biotechnology, and diagnostic companies. These transactions are essential to a company’s growth—aiding in the research, development, and commercialization of new products, as well as enabling clients to share risks and rewards, experience, and IP.
Transactions range from early-stage research platform deals to co-development and co-commercialization collaborations to co-promotion arrangements. In the course of structuring and negotiating this range of life science deals, our lawyers provide a variety of legal services, including IP, FDA/regulatory, real estate, tax, litigation prevention, and US and international governmental regulation. In addition, we assist clients with operational matters such as supply, distribution, and equity investment agreements.
We also represent academic institutions and industry partners in licensing technology and sponsoring research programs.
Our team advises private equity and venture capital firms on fund formation and other investment vehicles, and counsels pharmaceutical clients on their participation in these funds and formation of in-house funds.
In connection with M&A transactions, we counsel life science clients on product-related M&A as well as securities-related aspects of public and private mergers, divestitures, and joint ventures. We handle transactions of varying sizes, up to more than $50 billion, and of different types, including negotiated-purchases and divestitures, tender offers, proxy contests, restructurings, leveraged buyouts, and going private transactions. We also represent investment banks and commercial banks, venture capital firms, institutional lenders, independent directors committees, and management groups in M&A matters.
Morgan Lewis maintains close professional relationships with venture capital firms around the world. We understand how they operate, their diverse investment strategies, and their unique legal requirements. Our lawyers have participated in venture funding of emerging growth companies totaling more than $5 billion in the last five years alone.
We regularly advise venture fund (VC) sponsors on a range of legal matters, from investment transactions, to legal issues related to the formation of new funds, to structuring new financial arrangements for general partners and managing directors. We advise on the legal matters every company faces: tax, financing, employment, employee benefits, and best governance practices. In addition, we use our experience with hundreds of emerging companies to assist VC companies in planning ahead to maximize value from initial public offerings, mergers and acquisitions (M&A), and other liquidity alternative opportunities.
Our firm has a strong reputation in the VC community for our work with VC firms and other private investment funds. Our connections to financing sources and entrepreneurs have resulted in close relationships with the VC communities in the New York, Mid-Atlantic, Silicon Valley, and global markets.
Each of our clients works with a dedicated, partner-led team familiar with the client’s business objectives, industry dynamics, and market issues. Our goal is to provide VC firms with the guidance to create a strong foundation for success. We work closely with clients to negotiate strategic partnerships and to ensure that their portfolio investments are undertaken with proper due diligence. We appreciate and understand the details involved in exit transactions, sales of investments, and secondary transactions. We also play a strategic role in the day-to-day operations of VC firms—guiding them on a path to future success.
Our experience within industry-specific areas such as clean technology, energy, software, wireless technology, Internet, and life sciences provides us with the necessary knowledge of portfolio companies required by VC firms. By representing these portfolio companies, we understand the strategies essential for success—those leading to a reward on a client’s investment. And our securities and M&A practices have proven track records in managing successful exits.
Representing clients with trillions of dollars in assets under management, we have one of the largest investment management practices in the world. From our offices in financial centers in North America, Europe, Asia, and the Middle East, our team advises funds, managers, investment companies, investment advisers, broker-dealers, banks and trust companies, insurers, institutional investors, and other industry participants on the full spectrum of legal advice, including formation, investment, transactional, regulatory, and compliance.
Morgan Lewis’s lawyers understand venture investments and the particular needs of strategic investors, whether they are investing from the corporate treasury or through dedicated corporate venture capital entities and funds. The sensitivities associated with these strategic investments give rise to business issues and legal needs not found in other financial investments. Our attorneys, who have been providing critical advice in this arena during these competitive economic times, represent strategic investors for companies of all sizes around the world seeking business synergies, financial return, and future opportunities from these investments.
Our global team, which includes a deep bench of litigation and employment lawyers, regularly advises strategic investors and corporate venture capital funds on merger and acquisition rights, portfolio investments, and the formation of new funds, among other matters, including:
We also offer complete solutions to strategic and corporate venture investors, including: